Skip to main content
. 2016 May 9;2016(5):CD000544. doi: 10.1002/14651858.CD000544.pub4

Paoluzi 2005.

Methods Single center, randomized, investigator‐blind trial
Participants Adult patients (> 18 years) with confirmed ulcerative colitis in clinical, endoscopic and histological remission (N = 156)
Interventions Asacol 2.4 g/day (n = 80) or 1.2 g/day (n = 76) for 12 months
Outcomes Primary: maintenance of remission (Truelove and Witts). Secondary: time to relapse, adverse events
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence generation (selection bias) Unclear risk Not described
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection bias) 
 All outcomes Low risk Investigator‐blinded
Incomplete outcome data (attrition bias) 
 All outcomes Low risk Drop‐outs balanced across intervention groups with similar reasons for withdrawal
Selective reporting (reporting bias) Low risk Expected outcomes were reported
Other bias Low risk The study appears to be free of other sources of bias